AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39230120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab monotherapy
Number of subjects: 0
Study 39230120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab-based combination therapy
Number of subjects: 0
Study 39230120 — intervention group
Group type: EXPERIMENTAL
Intervention: Coformulated immunotherapy
Number of subjects: 0
Study 39230469 — intervention group
Group type: EXPERIMENTAL
Intervention: Research ultrasound of the carotid arteries
Number of subjects: 0
Study 39230469 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys on experience with the process
Number of subjects: 0
Study 39230469 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys on perception of personal risk of stroke
Number of subjects: 0
Study 39230469 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for changes in medical care
Number of subjects: 0
Study 39230544 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for Atrial Fibrillation using a 14-day continuous electrocardiographic monitor
Number of subjects: 11905
Study 39230544 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11905
Study 39230545 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (6 g, 4 weekly infusions)
Number of subjects: 18119
Study 39230545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18119
Study 39230571 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin plus Pembrolizumab (EV + Pembro)
Number of subjects: 886
Study 39230571 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin or carboplatin plus gemcitabine (Plat + Gem)
Number of subjects: 886
Study 39230576 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated laminar cartilage T2 relaxation time analysis method
Number of subjects: 72
Study 39230576 — intervention group
Group type: COMPARATOR
Intervention: Manual expert analysis
Number of subjects: 72
Study 39230668 — intervention group
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 103
Study 39230668 — intervention group
Group type: COMPARATOR
Intervention: InSTI+TAF/FTC
Number of subjects: 103
Study 39230672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE) for bothersome LUTS
Number of subjects: 478
Study 39230672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE) for acute urinary retention (AUR)
Number of subjects: 478
Study 39230672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 478
Study 39230678 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching doctors for a mean of 4.36 sessions
Number of subjects: 7254
Study 39230678 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7254
Study 39230757 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention for 20 min each day for three consecutive days
Number of subjects: 88
Study 39230757 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy intervention for 20 min each day for three consecutive days
Number of subjects: 88
Study 39230757 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and aromatherapy combined for 20 min each day for three consecutive days
Number of subjects: 88
Study 39230757 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 39230829 — intervention group
Group type: EXPERIMENTAL
Intervention: 350/700 mg BAM + ETE
Number of subjects: 354
Study 39230829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 39230871 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT510
Number of subjects: 567
Study 39230871 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 567
Study 39230871 — intervention group
Group type: COMPARATOR
Intervention: SCT510 and Bevacizumab
Number of subjects: 567
Study 39230885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg daily)
Number of subjects: 282
Study 39230885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 39230885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 282
Study 39230903 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking (EAW) device
Number of subjects: 161
Study 39230903 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) wheelchair use
Number of subjects: 161
Study 39231015 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) screening for AF and anticoagulation upon detection
Number of subjects: 6003
Study 39231015 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6003
Study 39231130 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care Model
Number of subjects: 0
Study 39231146 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere Length (TL)
Number of subjects: 84
Study 39231146 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomerase Activity (TA)
Number of subjects: 84
Study 39231146 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 84
Study 39231213 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neural networks (DNNs) for activity classification
Number of subjects: 13
Study 39231342 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of Lu AG09222
Number of subjects: 237
Study 39231342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 39231341 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Trabectedin (6 cycles)
Number of subjects: 150
Study 39231341 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (6 cycles)
Number of subjects: 150
Study 39231343 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 514
Study 39231343 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 514
Study 39231343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 39231343 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 514
Study 39231380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial implantation of SB623 cells (2.5 × 10^6 cells)
Number of subjects: 63
Study 39231380 — intervention group
Group type: COMPARATOR
Intervention: Sham control (surgical procedure without cell implantation)
Number of subjects: 63
Study 39231444 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) induction therapy for 12 weeks
Number of subjects: 0
Study 39231546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 MRI+ subgroup
Number of subjects: 657
Study 39231546 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary 2021 MRI+ subgroup
Number of subjects: 657
Study 39231546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 MRI+ but preliminary 2021 MRI- subgroup (53/657, 8.1%)
Number of subjects: 657
Study 39231546 — intervention group
Group type: COMPARATOR
Intervention: MRI- patients
Number of subjects: 657
Study 39231549 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics Navigator combined with usual care by a genetics clinician (physician or counsellor)
Number of subjects: 130
Study 39231549 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 130
Study 39231617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat once daily
Number of subjects: 0
Study 39231617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat three times weekly
Number of subjects: 0
Study 39231617 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39231735 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying position
Number of subjects: 60
Study 39231735 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 60
Study 39231780 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement for adolescents and young adults (CAE-AYA)
Number of subjects: 36
Study 39231780 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 36
Study 39231855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nofazinlimab 200 mg every 3 weeks (Q3W)
Number of subjects: 107
Study 39231855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nofazinlimab plus lenvatinib
Number of subjects: 107
Study 39231871 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 29
Study 39231871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 39231898 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7) infusion at 10 mcg/Kg day for a maximum of 7 days (Phase 2)
Number of subjects: 107
Study 39231898 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 107
Study 39232249 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-Based Injury Prevention Program (EIPP)
Number of subjects: 840
Study 39232261 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based rapid nutritional diagnostic system
Number of subjects: 5763
Study 39232261 — intervention group
Group type: COMPARATOR
Intervention: Control (no AI-based assessment)
Number of subjects: 5763
Study 39232408 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (nab-P) 100 mg/m² on days 1 and 8, carboplatin (C) on day 1, every 3 weeks for 6 cycles
Number of subjects: 23
Study 39232408 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (nab-P) and carboplatin (C)
Number of subjects: 23
Study 39232460 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient induction of labour methods
Number of subjects: 27
Study 39232460 — intervention group
Group type: EXPERIMENTAL
Intervention: New technologies of induction
Number of subjects: 27
Study 39232496 — intervention group
Group type: EXPERIMENTAL
Intervention: CMG901 (Claudin18.2-specific antibody-drug conjugate)
Number of subjects: 0
Study 39232601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low MUAC and low WHZ
Number of subjects: 0
Study 39232601 — intervention group
Group type: COMPARATOR
Intervention: Low MUAC-only
Number of subjects: 0
Study 39232601 — intervention group
Group type: COMPARATOR
Intervention: Low WHZ-only
Number of subjects: 0
Study 39232602 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (1 g twice daily for 14 days)
Number of subjects: 1126
Study 39232602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1126
Study 39232602 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina
Number of subjects: 1126
Study 39232634 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 to 150 mg every 2 weeks subcutaneously
Number of subjects: 18924
Study 39232634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 39232667 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital movement and music intervention (12 weeks, 3 sessions per week: 2 movement and music sessions, 1 music-only session)
Number of subjects: 34
Study 39232667 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital movement and music intervention
Number of subjects: 34
Study 39232668 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared meditation (4 mixed groups of 8 patients, 4 health professionals, and 4 third parties)
Number of subjects: 96
Study 39232668 — intervention group
Group type: COMPARATOR
Intervention: Patient meditation (2 groups of 16 patients)
Number of subjects: 96
Study 39232703 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided extraoral mandibular nerve block
Number of subjects: 36
Study 39232703 — intervention group
Group type: COMPARATOR
Intervention: Intraoral inferior alveolar nerve block
Number of subjects: 36
Study 39232708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Stabilization Exercises (NSE)
Number of subjects: 60
Study 39232708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Exercises (NDE)
Number of subjects: 60
Study 39232708 — intervention group
Group type: COMPARATOR
Intervention: NSE
Number of subjects: 60
Study 39232708 — intervention group
Group type: COMPARATOR
Intervention: NDE
Number of subjects: 60
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-space offices
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-distance trains
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Convenience stores
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-away delivery
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Car-pooling with relatives
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxis
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Airplanes
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerts
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-clubs
Number of subjects: 175688
Study 39232732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bars and restaurants
Number of subjects: 175688
Study 39232732 — intervention group
Group type: COMPARATOR
Intervention: Short-distance shared transport, car-pooling booked over platforms, markets, supermarkets and malls, hairdressers, museums, movie theatres, outdoor sports, swimming pools
Number of subjects: 175688
Study 39232748 — intervention group
Group type: COMPARATOR
Intervention: Paleolithic diet
Number of subjects: 13
Study 39232748 — intervention group
Group type: COMPARATOR
Intervention: Diabetes diet
Number of subjects: 13
Study 39232760 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder massage administered twice at 6-hour intervals
Number of subjects: 60
Study 39232760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 60
Study 39232761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib 60 mg BID plus mFOLFIRINOX q2w for 8-12 cycles followed by maintenance fuzuloparib at 150 mg BID
Number of subjects: 39
Study 39232761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib 30 mg BID
Number of subjects: 39
Study 39232761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib 60 mg BID
Number of subjects: 39
Study 39232761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib 100 mg BID
Number of subjects: 39
Study 39232761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib plus mFOLFIRINOX
Number of subjects: 39
Study 39232778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl test strip education and distribution
Number of subjects: 2400
Study 39232778 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (no fentanyl test strip education or distribution)
Number of subjects: 2400
Study 39232779 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 20995
Study 39232779 — intervention group
Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 20995
Study 39232781 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentum preservation during gastrectomy
Number of subjects: 654
Study 39232781 — intervention group
Group type: COMPARATOR
Intervention: Complete omentectomy during gastrectomy
Number of subjects: 654
Study 39232792 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical training programme (progressive and supervised endurance, resistance and balance training for 4 weeks, twice weekly sessions, total of 8 sessions)
Number of subjects: 0
Study 39232792 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 39232792 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical training programme
Number of subjects: 0
Study 39232795 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional lung protective ventilation plus sigh volumes producing plateau pressures of 35 cmH2O
Number of subjects: 192
Study 39232795 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung protective ventilation
Number of subjects: 192
Study 39232840 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane A
Number of subjects: 300
Study 39232840 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane B
Number of subjects: 300
Study 39232840 — intervention group
Group type: COMPARATOR
Intervention: Latex C
Number of subjects: 300
Study 39232999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive pneumatic compression
Number of subjects: 2003
Study 39232999 — intervention group
Group type: COMPARATOR
Intervention: Risk assessment models (Caprini, Padua, Intermountain, ICU-VTE, Kucher, IMPROVE)
Number of subjects: 2003
Study 39233015 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan-based hematopoietic cell transplantation (HCT) with PT/Cy for GVHD prophylaxis
Number of subjects: 36
Study 39233015 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan-based HCT with PT/Cy
Number of subjects: 36
Study 39233015 — intervention group
Group type: EXPERIMENTAL
Intervention: PT/Cy for GVHD prophylaxis
Number of subjects: 36
Study 39233117 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONGkids tool (high risk)
Number of subjects: 345
Study 39233117 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONGkids tool (moderate risk)
Number of subjects: 345
Study 39233117 — intervention group
Group type: COMPARATOR
Intervention: AAIMp tool (mild, moderate, severe malnutrition)
Number of subjects: 345
Study 39233210 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg daily
Number of subjects: 2770
Study 39233210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2770
Study 39233211 — intervention group
Group type: EXPERIMENTAL
Intervention: High LVEF (>65%)
Number of subjects: 370
Study 39233211 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal LVEF (55%-65%)
Number of subjects: 370
Study 39233211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EF (<55%)
Number of subjects: 370
Study 39233211 — intervention group
Group type: COMPARATOR
Intervention: Age comparison
Number of subjects: 370
Study 39233211 — intervention group
Group type: EXPERIMENTAL
Intervention: LV cavity volume
Number of subjects: 370
Study 39233211 — intervention group
Group type: EXPERIMENTAL
Intervention: LV mass-volume ratio
Number of subjects: 370
Study 39233211 — intervention group
Group type: EXPERIMENTAL
Intervention: LV end-systolic elastance
Number of subjects: 370
Study 39233211 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion reserve index (MPRI)
Number of subjects: 370
Study 39233312 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg once daily
Number of subjects: 154
Study 39233312 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan 200 mg once daily
Number of subjects: 154
Study 39233711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir + optimized background therapy
Number of subjects: 272
Study 39233850 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus Mindful Journey
Number of subjects: 34
Study 39233850 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 34
Study 39233999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular lubricants, used four times a day for 30 days
Number of subjects: 173
Study 39234256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 0
Study 39234256 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC; daratumumab plus pomalidomide and dexamethasone [DPd] or pomalidomide plus bortezomib and dexamethasone [PVd])
Number of subjects: 0
Study 39234416 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg each) administered subcutaneously every 4 weeks (n=9)
Number of subjects: 20
Study 39234416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 20
Study 39234619 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 41
Study 39234619 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 41
Study 39234862 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, bendamustine, and rituximab (ABR) in TN cohort
Number of subjects: 38
Study 39234862 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, bendamustine, and rituximab (ABR) in R/R cohort
Number of subjects: 38
Study 39234997 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted CARING intervention for rural cancer caregivers
Number of subjects: 10
Study 39234997 — intervention group
Group type: EXPERIMENTAL
Intervention: enCompass intervention
Number of subjects: 10
Study 39235326 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (12 cycles)
Number of subjects: 179
Study 39235326 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX (8 cycles) followed by LV5FU2 maintenance
Number of subjects: 179
Study 39235488 — intervention group
Group type: EXPERIMENTAL
Intervention: AHNAK1/2-mutant ESCC
Number of subjects: 201
Study 39235488 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of AHNAK in ESCC cell lines
Number of subjects: 201
Study 39235488 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-gene signature
Number of subjects: 201
Study 39235488 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular classification scheme
Number of subjects: 201
Study 39235513 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium hypochlorite/amino acid gel and crosslinked hyaluronic acid (xHyA) with subgingival instrumentation
Number of subjects: 52
Study 39235513 — intervention group
Group type: COMPARATOR
Intervention: subgingival instrumentation alone
Number of subjects: 52
Study 39235596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib monotherapy
Number of subjects: 111
Study 39235596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib plus tislelizumab
Number of subjects: 111
Study 39235596 — intervention group
Group type: COMPARATOR
Intervention: Sitravatinib monotherapy and sitravatinib plus tislelizumab
Number of subjects: 111
Study 39235639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) shock microcycles with a focus on time spent in zone 3 (Z3) or the 'red zone'.
Number of subjects: 0
Study 39235639 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate-based training decisions during HIIT-SM.
Number of subjects: 0